toxoplasmosis Treatment Drugs Global Market Report 2024

The toxoplasmosis treatment drugs market size has grown strongly in recent years. It will grow from $3.16 billion in 2023 to $3.36 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The historical period's expansion can be ascribed to restricted treatment alternatives, heightened awareness of toxoplasmosis, a rising incidence of toxoplasmosis, the development of healthcare infrastructure, and changes in the regulatory environment.

The toxoplasmosis treatment drugs market size is expected to see strong growth in the next few years. It will grow to $4.18 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The expansion anticipated in the forecast period can be credited to investments in research and development, the emergence of therapies for toxoplasmosis, a rise in healthcare spending, worldwide initiatives for controlling infectious diseases, and the adoption of personalized medicine approaches. Notable trends during the forecast period encompass the development of combination drug therapies, the integration of precision medicine into treatment strategies, a focus on early diagnosis and intervention, personalized treatment regimens, and advancements in drug delivery methods.

The anticipated rise in the prevalence of toxoplasmosis infections is poised to drive the growth of the market for drugs treating toxoplasmosis. Toxoplasmosis, a term encompassing infection and illness caused by the protozoan parasite Toxoplasma gondii in both humans and animals, necessitates drugs such as pyrimethamine, spiramycin, and leucovorin for treatment. This surge in toxoplasmosis infections, particularly the congenital type, as reported by the Centers for Disease Control and Prevention in August 2021, with an estimated global incidence of 190,100 cases per year, contributes to the expansion of the toxoplasmosis treatment drug market. The incidence rate is 1.5 cases per 1,000 live births, with a disease burden of 1.2 million disease-adjusted life years (DALYs) annually.

The growing elderly population is expected to be a significant driver of the toxoplasmosis treatment drug market. Geriatrics, the medical care of older individuals, poses challenges in defining this age category accurately. Effectively addressing toxoplasmosis in the geriatric population requires a comprehensive approach, balancing efficacy and safety through personalized treatment plans, research into new drugs, therapeutic methods, and a focus on prevention. Notably, data from the World Trade Organization in October 2022 revealed an increase in the population aged 60 and above from 1 billion to 1.4 billion between 2020 and 2021. Projections indicate a doubling of the world's population of adults aged 60 and above to 2.1 billion by 2050, with the number of people aged 80 or more expected to triple, reaching 426 million. Consequently, the rising geriatric population is a significant factor propelling the growth of the toxoplasmosis treatment drug market.

Innovation in product offerings emerges as a prominent trend in toxoplasmosis treatment drugs. Leading companies in the market are actively developing advanced products to maintain their market position. An example of this trend is Meitheal Pharmaceuticals, a US-based pharmaceutical company, which, in September 2023, introduced Leucovorin Calcium for Injection in five different forms. These forms include single-dose vials containing 50 mg, 100 mg, 200 mg, 350 mg, and 500 mg. The intended use of leucovorin calcium for injection is in conjunction with high-dose methotrexate therapy for osteosarcoma.

Strategic investments are a key focus for major players in the toxoplasmosis treatment drug market. Such investments are made with a long-term objective, such as gaining a competitive edge, entering new markets, or developing innovative technologies. For instance, ASTRA Therapeutics, a UK-based drug development company, secured funding of CHF 150,000 ($173,787.15) in April 2023. This investment is earmarked for the development of therapies addressing parasite diseases such as malaria, cryptosporidiosis, and toxoplasmosis, which adversely affect millions of people globally and result in significant disease and productivity losses in cattle and agriculture.

In August 2023, Vyera Pharmaceuticals, LLC, a Switzerland-based pharmaceutical company, engaged in an asset purchase agreement with Phoenixus AG, a Swiss-based biopharmaceutical company. Through this agreement, both companies aim to sell the rights to Daraprim, a prescription drug containing pyrimethamine used for treating toxoplasmosis when combined with a sulfonamide, and Vecamyl, used to treat moderately severe to severe essential hypertension, as well as simple cases of malignant hypertension.

Major companies operating in the toxoplasmosis treatment drugs market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca PLC, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals Inc., Lupin Ltd., Alvogen Group Inc., Manus Aktteva Biopharma LLP.

North America was the largest region in the toxoplasmosis treatment drugs market in 2023. The regions covered in the toxoplasmosis treatment drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the toxoplasmosis treatment drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of drug classes in the toxoplasmosis treatment drugs market include pyrimethamine, spiramycin, leucovorin, sulfadiazine, folic acid, and other variations. Chronic toxoplasmosis infection refers to a prolonged infection caused by the protozoan parasite Toxoplasma gondii. Indications for these drugs include both chronic toxoplasmosis infection and acute toxoplasmosis infection. The administration of these drugs can be through parenteral or oral routes and distribution occurs through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The toxoplasmosis treatment drugs market research report is one of a series of new reports that provides toxoplasmosis treatment drugs market statistics, including toxoplasmosis treatment drugs industry global market size, regional shares, competitors with a toxoplasmosis treatment drugs market share, detailed toxoplasmosis treatment drugs market segments, market trends and opportunities, and any further data you may need to thrive in the toxoplasmosis treatment drugs industry. This toxoplasmosis treatment drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The toxoplasmosis treatment drug market consists of sales of clindamycin and atovaquone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.